Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed, 118 citations in OpenAlex.

1. The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncontrolled diabetes.BMC research notes · 2022
   Trial
2. Type 2 Diabetes From the Perspective of Telomere Biology.Endocrinology, diabetes & metabolism · 2026
   Review
3. Targeting aging and age-related diseases with vaccines.Nature aging · 2024
   Review
4. Schizophrenia and obesity: May the gut microbiota serve as a link for the pathogenesis?iMeta · 2023
   Review
5. Interferon Family Cytokines in Obesity and Insulin Sensitivity.Cells · 2022
   Review
6. Advances in T Cells Based on Inflammation in Metabolic Diseases.Cells · 2022
   Review
7. Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022
   Article
8. Emodin Alleviates High-Glucose-Induced PancreaticEvidence-based complementary and alternative medicine : eCAM · 2022
   Article
9. lncRNA DRAIR is downregulated in diabetic monocytes and modulates the inflammatory phenotype via epigenetic mechanisms.JCI insight · 2021
   Article
10. Type 2 diabetes and viral infection; cause and effect of disease.Diabetes research and clinical practice · 2021
    Review
11. Suppressing adipocyte inflammation promotes insulin resistance in mice.Molecular metabolism · 2020
    Article
12. Research Progress on the Role of Inflammasomes in Kidney Disease.Mediators of inflammation · 2020
    Review
13. Inflammasome inhibitors: promising therapeutic approaches against cancer.Journal of hematology & oncology · 2019
    Review
14. Wu-Mei-wan protects pancreatic β cells by inhibiting NLRP3 Inflammasome activation in diabetic mice.BMC complementary and alternative medicine · 2019
    Article
15. Betaine Inhibits Interleukin-1β Production and Release: Potential Mechanisms.Frontiers in immunology · 2018
    Review
16. BACE2 suppression promotes β-cell survival and function in a model of type 2 diabetes induced by human islet amyloid polypeptide overexpression.Cellular and molecular life sciences : CMLS · 2017
    Article
17. β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation.Oncotarget · 2016
    Article
18. Filarial Infection or Antigen Administration Improves Glucose Tolerance in Diet-Induced Obese Mice.Journal of innate immunity · 2016
    Article
19. Circulating interleukin-1β promotes endoplasmic reticulum stress-induced myocytes apoptosis in diabetic cardiomyopathy via interleukin-1 receptor-associated kinase-2.Cardiovascular diabetology · 2015
    Article
20. NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia.Journal of diabetes research · 2015
    Article

Corrections and comments

• Comment on
  Interleukin-1-receptor antagonist in type 2 diabetes mellitus.2007

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as